WWHC (W World Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

WWHC does not currently pay a dividend.
See exactly how WWHC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WWHC and 80,000+ other tickers.
W World Corp. is a biopharmaceutical firm dedicated to identifying and advancing innovative treatments for various metabolic and neurological conditions. Its research and development efforts specifically target ailments related to the brain-gut axis, pain and inflammation, autoimmune diseases, and gout. The company's pipeline features two primary experimental drugs: Levotofisopam, currently in clinical trials as a non-sedative therapy for Gout, and Dextofisopam, a non-serotonergic compound that has successfully concluded Phase IIa and Phase IIb clinical trials for irritable bowel syndrome…
No recent news available.